9-Aminocamptothecin and beyond: Preclinical and clinical studies

Annals of the New York Academy of Sciences

Volumn 803, Issue , 1996, Pages 231-246

  Potmesil, Milan ^a   Arbuck, Susan G ^b   Takimoto, Chris H ^b   Liebes, Leonard ^a   Hochster, Howard ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; NSC 603071; UNCLASSIFIED DRUG;

CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG EFFICACY; HUMAN; META ANALYSIS; NONHUMAN; PHASE 1 CLINICAL TRIAL;

EID: 0030481439     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb26393.x     Document Type: Conference Paper

References (48)

1. WALL, M. E., M. C. WANI, S. M. NATSCHKE & A. W. NICHOLAS. 1986. Plant antitumor agents. 22. Isolation of 11-hydroxycamptothecin from Camptotheca acuminata Decne: total synthesis and biological activity. J. Med. Chem. 29: 1553.
2. WANI, M. C., A. W. NICHOLAS, G. MANIKUMAR & M. E. WALL. 1987. Plant antitumor agents. 25. Total synthesis and anti-leukemic activity of ring A substituted camptothecin analogues. Structure-activity correlations. J. Med. Chem. 30: 1774.
3. POTMESIL, M., & H. PINEDO Eds. 1995. Camptothecins: New Anticancer Agents. CRC Press, Inc. Boca Raton, FL.
4. LIU, L. F., Ed. 1994. DNA Topoisomerases: Topoisomerase-targeting Drugs. Academic Press. New York.
5. JAXEL, C., K. W. KOHN, M. C. WANI, M. E. WALL & Y. POMMIER. 1989. Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I. Evidence for a specific receptor site and for a relation to antitumor activity. Cancer Res. 49: 1465-1469.
6. HSIANG, Y.-H., L. F. LIU, M. E. WALL, M. C. WANI, S. KIRSCHENBAUM, R. SILBER & M. POTMESIL. 1989. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogs. Cancer Res. 49: 4385-4389.
7. GIOVANELLA, B. C., J. S. STEHLIN, M. E. WALL, M. C. WANI, A. W. NICHOLAS, L. F. LIU, R. SILBER & M. POTMESIL. 1989. DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246: 1046.
8. GIOVANELLA, B. C., H. R. HINZ, A. J. KOZIELSKI, J. S. STEHLIN, JR., R. SILBER & M. POTMESIL. 1991. Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20-(S)-camptothecin. Cancer Res. 51: 3052-3055.
9. POTMESIL, M., B. C. GIOVANELLA, L. F. LIU, M. E. WALL, J. S. SILBER, J. S. STEHLIN, JR., Y.-H. HSIANG & M. C. WANI. 1991. Preclinical studies of DNA topoisomerase I-targeted 9-amino and 10,11-methylenedioxy camptothecins. In DNA Topoisomerases in Cancer, M. Potmesil & K. W. Kohn Eds. p. 299. Oxford University Press. New York.
10. POTMESIL, M., B. C. GIOVANELLA, M. E. WALL, L. F. LIU, R. SILBER, J. S. STEHLIN, M. C. WANI & H. HOCHSTER. 1993. Preclinical and clinical development of DNA topoisomerase I inhibitors in the United States. In Molecular Biology of DNA Topoisomerases and its Application to Chemotherapy, Chapter 29: 301-311. T. Andoh, H. Ikeda & M. Oguro, Eds. CRC Press. Nagoya, Japan.
11. POTMESIL, M., D. VARDEMAN, A. J. KOZIELSKI, J. MENDOZA, J. S. STEHLIN, JR. & B. C. GIOVANELLA. 1995. Growth inhibition of human cancer metastases by camptothecins in newly developed xenograft models. Cancer Res. 55: 5637-5641.
12. Clinical Brochure 9-Amino-20(S)-camptothecin, NSC 603071, Investigational New Drug. Division of Cancer Treatment, National Cancer Institute, Bethesda, Maryland, 1992.
13. POTMESIL, M., & B. C. GIOVANELLA. Unpublished observations, 1992.
14. POTMESIL, M. 1994. Camptothecins: From bench research to hospital wards. Cancer Res. 54: 1431-1439.
15. SMITH, P. L., J. G. LIEHR, A. E. AHMED, H. R. HINZ, J. MENDOZA, A. KOZIELSKI, J. S. STEHLIN & B. C. GIOVANELLA. 1992. Pharmacokinetics of tritium labeled camptothecin in nude mice. Proc. Am. Assoc. Cancer Res. 33: 432.
16. POTMESIL, M., Z. N. CANELLAKIS, M. E. WALL, M. C. WANI, A. W. NICHOLAS, M. MANI, & R. SILBER. 1992. Pharmacokinetic studies of 9-amino-20(S)-camptothecin [NSC 603071]: Cellular partitioning. Proc. Am. Assoc. Cancer Res. 33: 433.
17. SUPKO, J. G., J. PLOWMAN, D. J. DYKES & D. S. ZAHARKO. 1992. Relationship between the schedule dependence of 9-amino-20(S)-camptothecin (AC; NSC 603071) antitumor activity in mice and its plasma pharmacokinetics. Proc. Am. Assoc. Cancer Res. 33: 432.
18. LIANG, M. D., W. DAHUT, M. F. QUIN, N. HAROLD, S. G. ARBUCK, A. CHEN, J. M. HAMILTON, J. M. SORENSEN, C. J. ALLEGRA, J. L. GREM & C. H. TAKIMOTO. 1996. Preclinical and clinical studies of a new colloidal dispersion formulation of 9-aminocamptothecin. Proc. Am. Assoc. Cancer Res. 37: 432.
19. RUBIN, E., V. WOOD, A. BHARTI, D. TRITES, C. LYNCH, S. HURWITZ, S. BARTEL, S. LEVY, A. ROSOWSKY, D. TOPPMEYER & D. KUFE. 1995. A phase I and pharmacokinetic study of a new camptothecin derivative, 9-aminocamptothecin. Clin. Cancer Res. 1: 269-276.
20. DAHUT, W., N. HAROLD, C. TAKIMOTO, C. ALLEGRA, A. CHEN, J. M. HAMILTON, S. ARBUCK, M. SORENSEN, F. GROLLMAN, H. NAKASHIMA, R. LIEBERMAN, M. LIANG, W. CORSE & J. GREM. 1996. Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients. J. Clin. Oncol. 14: 1236-1244.
21. GEOFFROY, F., W. DAHUT, C. H. TAKIMOTO & J. L. GREM. 1995. Effects of 9-aminocamptothecin on newly synthesized DNA in patient bone marrow samples. Clin. Cancer Res. 1: 1345-1351.
22. LANGEVIN, A. M., D. T. CASTO, J. G. KUHN, P. J. THOMAS & T. A. VIETTI. 1996. A phase I trial of 9-aminocamptothecin in children with refractory solid tumors - A Pediatric Oncology Group study. Abstract book, abstract #462, p. 130. Amsterdam, The Netherlands, March 12-15, 1996.
23. HOCHSTER, H., L. LIEBES, J. SPEYER, J. SORICH, B. TAUBES, J. ORATZ, J. WERNZ, A. CHACHOUA, B. RAPHAEL, R. Z. VINCI & R. H. BLUM. 1994. Phase I trial of low dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J. Clin. Oncol. 12: 553-559.
24. HOCHSTER, H., M. POTMESIL, L. LIEBES, J. SORICH, B. TAUBES, D. DEWEY, R. ORATZ, A. CHACHOUA & J. A. SPEYER. 1996. Phase I study of 9-aminocamptothecin (9-AC) by prolonged infusion of 21 days. 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Abstract book, abstract #461, p. 130. Amsterdam, The Netherlands, March 12-15, 1996.
25. TAKIMOTO, C. H., J. L. GREM, C. J. ALLEGRA & S. G. ARBUCK. 1996. Current status of the clinical development of 9-aminocamptothecin (9-AC). 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy. Abstract book, abstract #073, p. 26. Amsterdam, The Netherlands, March 12-15, 1996.
26. POTMESIL, M. & B. C. GIOVANELLA. 1995. Preclinical development of 20(S)-camptothecin, 9-aminocamptothecin and other analogs. In Camptothecins: New Anticancer Agents. M. Potmesil & H. Pinedo, Eds. Chapter 4: 51-57, CRC Press. Boca Raton, FL.
27. POTMESIL, M., L. LIEBES, J. DRYGAS, S. SEKIYA, H.CH. LEE, A. J. KOZIELSKI, M. E. WALL, M. C. WANI, J. S. STEHLIN & B. C. GIOVANELLA. Pharmacokinetics of intragastric 20(S)-camptothecin and analogs in the mouse model. Manuscript in preparation.
28. WILSON, W. H., D. PEARSON, R. HUMPHREY, D. KOHLER & S. STEINBERG. 1996. A phase II and dose escalation study ±G-CSF of 9-amino-camptothecin (9-AC) in relapsed lymphoma. Abstract book, abstract #464, p. 131. Amsterdam, The Netherlands, March 12-15, 1996.
29. VOKES, E. E., R. ANSARI, H. MINAMI, G. A. MASTERS, P. C. HOFFMAN, D. SCIORTINO, J. W. KUGLER, H. M. GOLOMB & M. J. RATAIN. 1996. A phase II and pharmacological study of 9-aminocamptothecin (9-AC) in advanced non-small cell lung cancer (NSCLC). Abstract book, abstract #463, p. 130. Amsterdam, The Netherlands, March 12-15, 1996.
30. SALTZ, L., N. KEMENY, S. SOIGNET, V. QUAN, J. HARRISON, R. BERKERY & D. KELSEN. 1996. A phase II study of 9-aminocamptothecin (9-AC) in patients with fluorouracil-refractory colorectal cancer. Program/Proceedings American Society of Clinical Oncology, Thirty-Second Annual Meeting, abstract 456, p. 204. Philadelphia, PA, May 18-21, 1996.
31. POTMESIL, M., L. LIEBES, J. DRYGAS, S. SEKIYA, H.CH. LEE, A. J. KOZIELSKI, M. E. WALL, M. C. WANI & B. C. GIOVANELLA. 1996. Novel camptothecins with lipophilic moieties. Proc. Am. Assoc. Cancer Res. 37: 432.
32. COSTIN, D., R. SILBER, Z. N. CANELLAKIS, L. MORSE & M. POTMESIL. 1992. Uptake of 20(S)-camptothecin (CAM) and analogs by human colon cancer cells or by chronic lymphocytic leukemia. In The Fourth Conference on DNA Topoisomerase in Therapy, Program and Abstracts, p. 53. New York, 1992.
33. SUPKO, J. G. & L. MALSPEIS. 1992. Liquid chromatographic analysis of 9-aminocamptothecin in plasma monitored by fluorescence induced upon postcolumn acidification. J. Liq. Chromatogr. 15: 3261-3283.
34. SUPKO, J. G. & L. MALSPEIS. 1993. Pharmacokinetics of the 9-amino and 10,11-methylenedioxy derivatives of camptothecin in mice. Cancer Res. 53: 3062-3069.
35. TAKIMOTO, C. H., R. W. KLECKER, W. L. DAHUT, L. K. YEE, J. M. STRONG, C. J. ALLEGRA & J. L. GREM. 1994. Analysis of the active lactone form of 9-aminocamptothecin in plasma using solid-phase extraction and high-performance liquid chromatography. J. Chromatogr. B 655: 97-104.
36. ROWINSKY, E. K., L. B. GROCHOW, C. B. HENDRICKS, D. S. ETTINGER, A. A. FORASTIERE, L. A. HUROWITZ, W. P. MCGUIRE, S. E. SARTORIUS, B. G. LUBEJKO, S. H. KAUFMAN & R. C. DONEHOWER. 1992. Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor. J. Clin. Oncol. 10: 647-656.
37. BLANEY, S. M., F. M. BALIS, D. E. COLE, C. CRAIG, J. M. REID, M. M AMES, M. KRAILO, G. REAMAN, D. HAMMOND & D. POPLACK. 1993. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res. 53: 1032-1036.
38. ROWINSKY, E. K., L. B. GROCHOW, D. S. ETTINGER, S. E. SARTORIUS, B. G. LUBEJKO, T.-L. CHEN, M. K. ROCK & R. C. DONEHOWER. 1994. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperdino)-1-piperidino]-carbonyloxycamptothecin (CPT-11) administered as a 90 minute infusion every 3 weeks. Cancer Res. 54: 427-436.
39. ROTHENBERG, M. L., J. G. KUHN, H. A. BURRIS III, J. NELSON, J. R. ECKHARDT, M. TRISTAN-MORALES, S. G. HILSENBECK, G. R. WEISS, L. S. SMITH, G. I. RODRIGUES, M. ROCK & D. VON HOFF. 1993. Phase I and pharmacokinetic trial of weekly CPT-11. J. Clin. Oncol. 11: 2194-2204.
40. RIVORY, L. P., E. CHATELEUT, P. CANAL, P. CANAL, A. MATHIEU-BOUE & J. ROBERT. 1994. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and of its metabolite SN-38 in patients. Cancer Res. 54: 6330-6333.
41. BURKE, T. G. & Z. MI. 1994. The structure basis of camptothecin interaction with human serum albumin. J. Med. Chem. 34: 40-46.
42. POTMESIL, M., L. LIEBES, J. DRYGAS, S. SEKIYA, H.CH. LEE, A. J. KOZIELSKI, M. E. WALL, M. C. WANI & B. C. GIOVANELLA. 1996. Camptothecins with lipophilic moiety as potential tools in regional chemotherapy. Program/Proceedings American Society of Clinical Oncology, Thirty-Second Annual Meeting, abstract 1600, p. 500. Philadelphia, PA, May 18-21, 1996.
43. TAKIMOTO, C. H. Unpublished results, 1996.
44. TAKIMOTO, C. H. & S. G. ARBUCK. 1996. The Camptothecins. In Cancer Chemotherapy and Biotherapy: Principles and Practice, 2nd edition. B. A. Chabner & D. L. Longo, Eds. p. 463-484. Lippincott-Raven Press. Philadelphia, PA.
45. MINAMI, H., R. MICK & M. J. RATAIN. 1996. Pharmacodynamic models for leukopenia and thrombocytopenia of 9-aminocamptothecin (9-AC). Program/Proceedings American Society of Clinical Oncology, Thirty-Second Annual Meeting, abstract 368, p. 179. Philadelphia, PA, May 18-21, 1996.
46. SILBER, R., B. DEGAR, D. COSTIN, E. W. NEWCOMB, M. MANI, C. R. ROSENBERG, L. MORSE, J. C. DRYGAS, Z. N. CANELLAKIS & M. POTMESIL. 1994. Chemosensitivity of lymphocytes from patients with B-cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood 84: 3440-3446.
47. GOLDWASSER, F., I. BAE, M. VALENTI, K. TORRES & Y. POMMIER. 1995. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma lines from the National Cancer Institute anticancer screen. Cancer Res. 55: 2116-2121.
48. D'ARPA, P., C. BEARDMORE & L. F. LIU. 1990. Involvement of nucleic acids in cell killing mechanisms of topoisomerase poisons. Cancer Res. 50: 6919-6924.